MoneyWorks4Me

Aurobindo Pharma turns black in Q1

12 Aug 2013 Evaluate

Aurobindo Pharma has reported results for first quarter ended June 30, 2013.

The company has reported a net profit of Rs 143.63 crore for the quarter as compared to a net loss of Rs 49.84 crore for the same quarter in the previous year. Total income of the company has increased by 42.81% at Rs 1614.61 crore for quarter under review as compared to Rs 1130.61 crore for the quarter ended June 30, 2012.

On the consolidated basis, the group registered a net profit after taxes and minority interest at Rs 18.60 crore for the quarter as compared to a net loss of Rs 128.91 crore for the same quarter in the previous year. Total income of the company, on consolidated basis, has increased by 41.33% at Rs 1719.48 crore for quarter under review as compared to Rs 1216.63 crore for the quarter ended June 30, 2012.

 

Aurobindo Pharma Share Price

1661.00 71.50 (4.50%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: